Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Neuronetics

From Wikipedia, the free encyclopedia
Neuronetics, Inc.
TypePublic
Nasdaq: STIM
Russell 2000 Index component
Founded2003
HeadquartersMalvern, PA, United States
Key people
Dan Reuvers
(President and CEO)[1][2]

Stephen Furlong (CFO)[1] Andrew Macan
(General counsel)[1]

[3]
Number of employees
167
As of March 31, 2018[4]
Websiteneurostar.com

Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003,[4] that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology. 

Neuronetics became the "first and only Food and Drug Administration (FDA) approval for the clinical treatment of a specific form of medication-refractory depression using a TMS Therapy device (FDA approval K061053)."[5]

They manufacture a transcranial magnetic stimulation device, NeuroStar.[6] The NeuroStar TMS therapy is delivered via a precisely positioned magnetic coil against the patient's head.

References

[edit]
  1. 1 2 3 "Neuronetics, Inc. Appoints Dan Reuvers as President and CEO".
  2. "Neuronetics names new CEO". Seeking Alpha. Retrieved July 15, 2020.
  3. "NeuroStar Executive Team". Neuronetics.
  4. 1 2 "Neuronetics, Inc. (stim) IPO". NASDAQ.com.
  5. Horvath, J. C.; Mathews, J.; Demitrack, M. A.; Pascual-Leone, A. (July 12, 2010). "The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression". Journal of Visualized Experiments (45): 2345. doi:10.3791/2345. PMC 3159591. PMID 21189465.
  6. "Hello Health: How transcranial magnetic stimulation treats major depressive disorder". November 11, 2020.
[edit]